| Primary domains | Secondary domains | ||
---|---|---|---|---|
 | Number | Percentage (%) | Number | Percentage (%) |
(1) Domains relating to the tinnitus percept: | ||||
 Tinnitus loudness | 70 | 14 % | 42 | 7 % |
 Tinnitus pitch | 12 | 2 % | 13 | 2 % |
(2) Domains relating to the impact of tinnitus: | ||||
 Tinnitus distress | 33 | 7 % | 18 | 3 % |
 Tinnitus annoyance | 22 | 4 % | 15 | 3 % |
 Tinnitus awareness | 10 | 2 % | 2 | 0 % |
 Cognition | 2 | 0 % | 4 | 1 % |
 Behaviour | 1 | 0 % | 0 | - |
 Acceptance of tinnitus | 0 | - | 3 | 1 % |
 Catastrophising | 0 | - | 1 | 0 % |
 Concentration | 0 | - | 2 | 0 % |
 Tinnitus intrusiveness | 0 | - | 2 | 0 % |
 Tinnitus-related cognitions | 0 | - | 1 | 0 % |
 Tinnitus-related fear | 0 | - | 1 | 0 % |
(3) Other co-occurring complaints: | ||||
 Depression | 8 | 2 % | 18 | 3 % |
 General distress | 5 | 1 % | 5 | 1 % |
 Anxiety | 4 | 1 % | 6 | 1 % |
 Anxiety and depression | 4 | 1 % | 13 | 2 % |
 Hearing threshold | 4 | 1 % | 11 | 2 % |
 Hearing loss | 2 | 0 % | 1 | 0 % |
 Speech perception | 2 | 0 % | 0 | - |
 Hearing handicap | 1 | 0 % | 3 | 1 % |
 Hearing loss annoyance | 1 | 0 % | 0 | - |
 Sleep quality | 1 | 0 % | 12 | 2 % |
 Somatic sensations | 1 | 0 % | 1 | 0 % |
 Fear (anxiety) | 0 | - | 1 | 0 % |
 Hyperacusis | 0 | - | 3 | 1 % |
 Mood | 0 | - | 2 | 0 % |
 Sound tolerance | 0 | - | 1 | 0 % |
 Speech discrimination | 0 | - | 3 | 1 % |
(4) Health-related quality of life (QoL): | ||||
 QoL (tinnitus) | 16 | 3 % | 13 | 2 % |
 QoL | 9 | 2 % | 20 | 3 % |
 Coping | 3 | 1 % | 0 | - |
 Occupational health | 0 | - | 1 | 0 % |
 QoL (hearing) | 0 | - | 1 | 0 % |
 Sense of control | 0 | - | 1 | 0 % |
(5) Body structures and functions: | ||||
 Neck mobility | 1 | 0 % | 1 | 0 % |
 Neural activity | 1 | 0 % | 2 | 0 % |
 Oxidative stress | 1 | 0 % | 0 | - |
 Active myofascial trigger points | 0 | - | 1 | 0 % |
 Blood parameters | 0 | - | 1 | 0 % |
 Gene expression | 0 | - | 1 | 0 % |
 Metabolism | 0 | - | 4 | 1 % |
 Neck pain | 0 | - | 1 | 0 % |
 Neuroendocrine hormones | 0 | - | 1 | 0 % |
 Pharmacokinetics | 0 | - | 1 | 0 % |
 Structural brain change | 0 | - | 1 | 0 % |
(6) Adverse events or harms: | ||||
 Safety and tolerability | 6 | 1 % | 4 | 1 % |
 Safety | 2 | 0 % | 43 | 7 % |
 Drug safety and tolerability | 1 | 0 % | 4 | 1 % |
 Side effects | 1 | 0 % | 15 | 3 % |
 Headache | 0 | - | 1 | 0 % |
 Pain frequency | 0 | - | 1 | 0 % |
 Pain intensity | 0 | - | 1 | 0 % |
(7) Satisfaction: | ||||
 Treatment satisfaction | 1 | 0 % | 5 | 1 % |
(8) Treatment-related outcomes: | ||||
 Withdrawals | 1 | 0 % | 0 | - |
 Adequacy of blinding | 0 | - | 1 | 0 % |
 Credibility (sham) | 0 | - | 1 | 0 % |
 Credibility (treatment) | 0 | - | 2 | 0 % |
 Needling sensation (acupuncture) | 0 | - | 1 | 0 % |
 Therapeutic alliance | 0 | - | 1 | 0 % |
 Tolerability | 0 | - | 5 | 1 % |
(9) Domain of interest unclear or not specified by the authors: | ||||
 Not specified | 128 | 25 % | 140 | 24 % |
 Cannot code | 58 | 11 % | 76 | 13 % |
 Multi-domain specification | 10 | 2 % | 10 | 2 % |
 Tinnitus severity | 69 | 14 % | 29 | 5 % |
 Tinnitus handicap | 14 | 3 % | 5 | 1 % |
Total | 505 | 100Â % | 579 | 100Â % |